LISCure Expands Global Partnerships for BBB Shuttle Platform ‘ExoPN-101’; Signs Fourth MTA with Leading Pharma Partner
LISCure Biosciences (“LISCure”), a biotechnology company advancing next-generation therapeutics, today announced that it has entered into a new Material Transfer Agreement (MTA) with a leading global pharmaceutical company for its proprietary blood-brain barrier (BBB) shuttle platform, ExoPN-101. https://mma.prnewswire.com/media/2818261/LISCure_Biosciences_Logo.jpg This marks LISCure's fourth MTA, further validating the technological innovation and commercial potential of the ExoPN-101 platform […]